A detailed history of Stifel Financial Corp transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 51,997 shares of LXRX stock, worth $50,957. This represents 0.0% of its overall portfolio holdings.

Number of Shares
51,997
Previous 51,451 1.06%
Holding current value
$50,957
Previous $86,000 5.81%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.51 - $2.39 $824 - $1,304
546 Added 1.06%
51,997 $81,000
Q2 2024

Aug 13, 2024

SELL
$1.54 - $2.28 $1,113 - $1,648
-723 Reduced 1.39%
51,451 $86,000
Q1 2024

May 13, 2024

BUY
$1.3 - $3.58 $16,278 - $44,828
12,522 Added 31.58%
52,174 $125,000
Q4 2023

Feb 12, 2024

SELL
$1.0 - $1.53 $42,315 - $64,741
-42,315 Reduced 51.62%
39,652 $60,000
Q3 2023

Nov 13, 2023

SELL
$1.06 - $2.33 $49,769 - $109,398
-46,952 Reduced 36.42%
81,967 $89,000
Q2 2023

Aug 14, 2023

BUY
$2.15 - $3.49 $1,307 - $2,121
608 Added 0.47%
128,919 $295,000
Q1 2023

May 12, 2023

BUY
$1.99 - $2.68 $7,615 - $10,256
3,827 Added 3.07%
128,311 $311,000
Q4 2022

Feb 13, 2023

SELL
$1.8 - $2.56 $21,958 - $31,229
-12,199 Reduced 8.93%
124,484 $237,000
Q3 2022

Nov 14, 2022

SELL
$1.94 - $3.43 $5,226 - $9,240
-2,694 Reduced 1.93%
136,683 $328,000
Q2 2022

Aug 15, 2022

BUY
$1.31 - $2.69 $8,289 - $17,022
6,328 Added 4.76%
139,377 $259,000
Q1 2022

May 13, 2022

BUY
$1.95 - $3.89 $53,878 - $107,480
27,630 Added 26.21%
133,049 $278,000
Q4 2021

Feb 14, 2022

SELL
$3.81 - $6.16 $39,985 - $64,649
-10,495 Reduced 9.05%
105,419 $415,000
Q3 2021

Nov 15, 2021

BUY
$3.38 - $5.35 $116,018 - $183,638
34,325 Added 42.07%
115,914 $558,000
Q2 2021

Aug 13, 2021

BUY
$4.12 - $5.87 $15,124 - $21,548
3,671 Added 4.71%
81,589 $374,000
Q1 2021

May 14, 2021

BUY
$3.45 - $9.09 $26,527 - $69,893
7,689 Added 10.95%
77,918 $457,000
Q4 2020

Feb 12, 2021

BUY
$1.05 - $3.67 $1,437 - $5,024
1,369 Added 1.99%
70,229 $240,000
Q3 2020

Nov 16, 2020

BUY
$1.44 - $2.1 $5,444 - $7,940
3,781 Added 5.81%
68,860 $99,000
Q2 2020

Aug 14, 2020

SELL
$1.75 - $2.3 $458 - $602
-262 Reduced 0.4%
65,079 $130,000
Q1 2020

May 14, 2020

SELL
$1.8 - $4.28 $12,229 - $29,078
-6,794 Reduced 9.42%
65,341 $126,000
Q4 2019

Feb 13, 2020

SELL
$3.16 - $5.15 $6,016 - $9,805
-1,904 Reduced 2.57%
72,135 $298,000
Q3 2019

Nov 13, 2019

SELL
$1.2 - $6.66 $204 - $1,132
-170 Reduced 0.23%
74,039 $227,000
Q2 2019

Aug 14, 2019

SELL
$5.35 - $7.11 $131,492 - $174,749
-24,578 Reduced 24.88%
74,209 $473,000
Q1 2019

May 14, 2019

SELL
$4.36 - $7.94 $32,952 - $60,010
-7,558 Reduced 7.11%
98,787 $556,000
Q4 2018

Feb 13, 2019

SELL
$6.15 - $10.51 $235,846 - $403,047
-38,349 Reduced 26.5%
106,345 $705,000
Q3 2018

Nov 13, 2018

BUY
$10.32 - $13.06 $159,237 - $201,515
15,430 Added 11.94%
144,694 $1.53 Million
Q2 2018

Aug 14, 2018

BUY
$7.8 - $13.69 $191,942 - $336,883
24,608 Added 23.51%
129,264 $1.55 Million
Q1 2018

May 11, 2018

BUY
$7.86 - $11.39 $113,011 - $163,765
14,378 Added 15.93%
104,656 $902,000
Q4 2017

Feb 14, 2018

BUY
$8.77 - $12.28 $86,463 - $121,068
9,859 Added 12.26%
90,278 $893,000
Q3 2017

Nov 13, 2017

BUY
$12.17 - $16.3 $978,699 - $1.31 Million
80,419
80,419 $0

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $185M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.